Combined targeting of PI3K and MEK effector pathways via CED for DIPG therapy.
Chang R, Tosi U, Voronina J, Adeuyan O, Wu LY, Schweitzer ME, Pisapia DJ, Becher OJ, Souweidane MM, Maachani UB.
Chang R, et al.
Neurooncol Adv. 2019 May 28;1(1):vdz004. doi: 10.1093/noajnl/vdz004. eCollection 2019 May-Dec.
Neurooncol Adv. 2019.
PMID: 32642647
Free PMC article.